loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Supriya Lifescience Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Supriya Lifescience Ltd. 14 Aug 2025 16:18 PM
Result PDF

Q1FY26 Quarterly Result Announced for Supriya Lifescience Ltd.

Pharmaceuticals company Supriya Lifescience announced Q1FY26 results

  • The company witnessed a 9.7% YoY decline in Revenue to Rs 145.07 crore compared to Rs 160.63 crore in Q1FY25.
  • EBITDA for Q1FY26 stood at Rs. 51.70 crore, with an EBITDA margin of 35.6%, as against Rs 62.54 crore in Q1FY25 with a margin of 38.9%.
  • The Profit After Tax (PAT) for Q1FY26 was Rs 34.79 crore, compared to RS 44.64 crore in Q1FY25.
  • The PAT Margin stood at 24.0% in Q1FY26 versus 27.8% in Q1FY25.
  • Anaesthetic segment led the revenue in Q1, contributing 53% to the revenue vs 45% in Q1FY25.
  • European markets now contribute 41% of our business revenue in Q1FY26, up from 34% in Q1FY25.

Satish Wagh, Chairman & Managing Director, Supriya Lifescience, said: “Our Q1 results reflect a temporary impact from the delay in the production facility campaign due to essential repair and maintenance at our Lote facility. These upgrades were critical to improving the efficiency of our older blocks and enabling full utilisation of Module E for upcoming product launches. Despite the revenue dip, EBITDA margins remained strong at 36%, backed by improved backwards integration and increased contribution from regulated markets. With the Ambernath site progressing towards commercial production in Q4, a strong pipeline of 3 to 4 product launches in FY26, and healthy demand across key therapeutic areas, we expect the second half to recover the delays from H1. We remain on track to deliver ~20% growth and reach Rs 1,000 crore revenue by FY27."

Result PDF

Result PDF

Pharmaceuticals company Supriya Lifescience announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • In the fourth quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 16.4 % year-over-year increase, reaching Rs 184.11 crore compared to Rs 158.18 crore in Q4FY24.
  • EBITDA for Q4FY25 stood at Rs 67.58 crore, with an EBITDA Margin of 36.7 %, as opposed to an EBITDA of Rs 55.5 crore in Q4FY24 with an EBITDA margin of 35.1%. This marks an improvement of 162 bps YoY.
  • Profit after Tax for Q4FY25 stood at Rs 50.38 crore, with a growth of 38.4% compared to Rs 36.40 crore in Q4FY24.
  • The PAT Margin stood at 27.4% in Q4FY25, compared to 23.0% in Q4FY24

FY25 Financial Highlights:

  • In FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 22% year-over-year increase, reaching Rs 696.48 crore compared to Rs 570.37 crore in FY24.
  • EBITDA for FY25 stood at Rs 260.80 crore, with an EBITDA Margin of 37.4 %, as opposed to an EBITDA of Rs 172.98 crore in FY24 with an EBITDA margin of 30.3%. This marks an improvement of 712 bps YoY.
  • Profit after Tax for FY25 stood at Rs 187.96 crore, with a growth of 57.8% compared to Rs 119.11 crore in FY24.
  • The PAT Margin stood at 27.0% in FY25, compared to 20.9% in FY24.

Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience commenting on the results, said, “FY25 has been a landmark year for Supriya Lifescience, reflecting the strength of our diversified product portfolio, resilient global operations, and consistent focus on operational excellence. We achieved our highest-ever annual revenue of Rs 697 crore, up 22% year-on-year, and delivered an EBITDA of Rs 261 crore with a robust margin of 37.4%. In Q4FY25, revenue grew by 16.4% to Rs 184.11 crore, while PAT rose by 38.4% to Rs 50.38 crore, supported by improved margins. Our strategic focus on high-value therapeutic segments, deeper penetration in regulated markets, and strengthened backward integration continue to drive our performance. We remain committed to building on this momentum to deliver sustainable growth, foster innovation, and create long-term value for all stakeholders.”

Result PDF

Pharmaceuticals company Supriya Lifescience announced Q3FY25 results

  • In the third quarter of FY25, Supriya Lifescience witnessed remarkable growth in its revenue, reporting a 33% year-over-year increase, reaching Rs 185.65 crore compared to Rs 140.07 crore in Q3FY24.
  • Gross Profit for Q3FY25 stood at Rs 123.87 crore, with a growth of 45% compared to Rs 85.45 crore in Q3FY24.
  • EBITDA for Q3FY25 stood at Rs 65.95 crore, with an EBITDA Margin of 35.50%, as opposed to an EBITDA of Rs 41.49 crore in Q3FY24 with an EBITDA margin of 29.60%. This marks an improvement of 591 bps YoY.
  • The Profit After Tax (PAT) increased by 57% for Q3FY25 to Rs 46.78 crore, compared to Rs 29.78 crore in Q3FY24.
  • The PAT Margin stood at 25.2% in Q3FY25, compared to 21.30% in Q3FY24.

Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience, commenting on the results, said, “Our Q3FY25 results underscore Supriya Lifescience’s commitment to delivering value through operational excellence and strategic growth initiatives. The 33% YoY revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments. The steady improvement in our EBITDA and PAT margins, reaching 35% and 25% respectively, highlights our ability to maintain profitability while investing in sustainable growth."

Result PDF

Pharmaceuticals company Supriya Lifescience announced H1FY25 & Q2FY25 results

  • In the second quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 18.6 % year-over-year increase, reaching Rs 166.1 crore compared to Rs 140.1 crore in Q2FY24.
  • Gross Profit for Q2FY255 stood at Rs 120.13 crore, with a growth of 53.1% compared to Rs 78.46 crore in Q2FY24.
  • EBITDA for Q2FY255 stood at Rs 64.72 crore, with an EBITDA Margin of 39.0%, as opposed to an EBITDA of Rs 31.75 crore in Q2FY24 with an EBITDA margin of 22.7%. This marks a growth of 103.8% YoY.
  • The Profit After Tax (PAT) for Q2FY255 came at Rs 46.15 crore, compared to Rs 23.88 crore in Q2FY24.
  • The PAT Margin stood at 27.8% in Q2FY255, compared to 17.0% in Q2FY24.
  • Analgesic and Anaesthetic segment led the business growth in Q2 contributing 54.9% to the revenue vs 50.0% in Q2FY24. Anti-Asthmatic segment contributed 9.2% compared to 7.2%.
  • European markets now contribute 45% of our business revenue in H1FY25 up from 39% in H1FY24.
  • For Anaesthetic therapy 3 ANDA projects have been initiated and company is also working on ANDA projects for Anti Hypertensive and Vitamins.
  • Capacity Utilisation has quickly increased from 47% in FY22 following a fresh capacity addition to 86% in FY24. In order to support future growth of various business segments the company has acquired three separate land parcels near different plants.
  • Supriya Lifescience Ltd. continues to expand its global footprint, now doing business with over 1,700 customers across more than 128 countries. To ensure sustained growth and further expansion through new customer acquisition, the company has strategically distributed these geographic regions among its dedicated sales teams

Satish Wagh, Executive Chairman & WTD, Supriya Lifescience commenting on the results, said: “Our commitment to innovation through R&D is paving the way for sustained growth and expansion. With the commissioning of our advanced R&D lab at Lote Parshuram and the upcoming Ambernath facility, we’re focusing on new product development and CMO/CDMO opportunities to complement our existing portfolio. Expanding our global presence across key regions, we're also working closely with regulatory and sales teams to acquire new customers, particularly in regulated markets. Our recent exclusive 10-year contract with a leading European firm underscores our capabilities in handling complex chemical processes, setting the stage for similar opportunities. As we enhance our infrastructure, including increasing capacity at Lote Parshuram to 1,020 KL by Q3FY25, we’re building a foundation for a stronger future."

Result PDF

Pharmaceuticals company Supriya Lifescience announced Q1FY25 results: 

  • In the first quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 21.7 % YoY increase, reaching Rs 160.63 crore compared to Rs 132.02 crore in Q1 FY24.
  • EBITDA for Q1 FY25 stood at Rs 62.54 crore, with an EBITDA Margin of 38.9%, as opposed to an EBITDA of Rs 44.49 crore in Q1 FY24 with an EBITDA margin of 33.7%. This marks a growth of 40.6% YoY. 
  • The Profit After Tax (PAT) for Q1 FY25 came at Rs 44.64 crore, compared to Rs 28.51 crore in Q1 FY24.
  • The PAT Margin stood at 27.8% in Q1 FY25, compared to 21.6% in Q1 FY24.
  • The company has seen good growth across different therapeutic areas in Q1FY25
  • European markets now contribute 51% of our business revenue up from 43% in Q4FY24 and 34% in Q1FY24. 

Saloni Wagh, Managing Director, Supriya Lifescience, commenting on the results, said, “We are engaged in discussions with a diverse range of companies, from major pharmaceutical firms to innovative enterprises, to establish partnerships for supplying tailored products. The company achieved a record capital expenditure of Rs 146 crore in the last financial year while also enhancing its return on equity by 210 basis points.

We're proud to unveil our new R&D facility at Lote Parshuram and anticipate the completion of our Ambernath lab by early Q2FY25. These state-of-the-art centers will drive our next phase of growth, focusing on advanced product development, CMO/CDMO opportunities, and expanding our portfolio to meet evolving market needs. Moving forward, the company aims for significant growth with improved profitability.”

Result PDF

Pharmaceuticals company Supriya Lifescience announced Q1FY24 results:

  • Total revenue of Rs 134.9 crore in Q1FY24, as compared to Rs 103.7 crore in Q1FY23
  • Total PAT of Rs 28.51 crore in Q1FY24, as compared to Rs 25.25 crore in Q1FY23
  • Reported PAT margin of 22%
  • Reported Gross profit of 64%
  • EBITDA reported Rs 44.49 crore in Q1FY24, as compared to Rs 31.25 crore in Q1FY23
  • Healthy EBITDA margin of 34% reported in Q1FY24
  • Asian market contributed over 40% of the business, whereas Europe contributed 35%

Satish Wagh, Chairman and Managing Director, Supriya Lifescience, commenting on their results said, “The company has been resilient to the global economic conditions and has delivered a strong comeback. Our strategic business initiatives of deeper penetration in existing markets and tapping new markets, backed by our world-class R&D capabilities, have been the key growth drivers for our business. The demand from regulated markets like Europe, North America, and Latin America have surged and come back to normalcy.”

 

 

 

Result PDF

Pharmaceuticals company Supriya Lifescience declares Q3FY22 result:

  • Consolidated Revenue for Q3FY22 reported a growth of 44 % (YoY) to Rs. 1,224.4 million as compared to Rs. 850.2 million in Q3FY21.
  • The current quarter performance was driven by very strong demand for anaesthetic, Antiasthmatic and Vitamin therapy. The company expects the demand for these therapies to be strong, also expect demand for antihistamine to pick up going forward.
  • Increase in Q3 sales was also driven by higher penetration in regulated markets like Europe and Latin America
  • Gross Profit for Q3 FY22 stood at Rs. 806.5 million as compared to Rs. 522.7 million in Q3 FY21 , a growth of 54% compared to same quarter last year.
  • EBITDA for Q3 FY22 stood at Rs. 438.2 million and EBITDA Margin stood at 36% as against Rs. 301.6 million in Q3 FY21 (35%), registering a growth of 45% (YoY)
  • PAT for Q3 FY22 stood at Rs. 396.4 million and PAT Margin stood at 32 % in Q3 FY21 as against Rs. 156.9 million in Q3FY21, registering a growth of 153%.

Commenting on the Results, Dr. Satish Wagh, Chairman & Managing Director, Supriya Lifescience said, “I would like to thank everyone for the overwhelming support we have received for our IPO. With this support and trust from the investors our IPO was oversubscribed by 71.47 times. The company has shown consistent performance for 9 months FY22 with an operating revenue of Rs 3,525.0 Mn with EBIDTA of Rs 1,424.8 Mn (40 % of Revenue) and PAT of Rs 1,056.0 Mn (30% of revenue). The current quarter performance was driven by very strong demand for anaesthetic, antiasthmatic and Vitamin products.

The fourth manufacturing block at our site got operational in May’21. We have also commenced the work for the next manufacturing block which is expected to get operational by FY23. This block will add 310 KL capacity. Two new warehouses for Finished Goods and Raw materials will get operational by Q1 FY23. A new Quality Control laboratory along with state-of-the-art R&D laboratory will be operational by Q2 FY23.

In line with company strategy to penetrate in more regulated markets, we have also applied for registering more products in US, European and Chinese markets “

Result PDF

Trending News

ACE and Sanghvi Movers have signed a strategic MoU

ACE and Sanghvi Movers have signed a strategic MoU

Published on 12-Dec-2025 09:05

Chalet Hotels has announced its plans to acquire a resort in Udaipur

 Chalet Hotels has announced its plans to acquire a resort in Udaipur

Published on 12-Dec-2025 09:04

Union Cabinet is expected to consider the Insurance Amendment Bill that proposes major regulatory changes

Union Cabinet is expected to consider the Insurance Amendment Bill that proposes major regulatory changes

Published on 12-Dec-2025 09:01

Mexico government has announced raising import tariffs on vehicles, two-wheelers, and auto parts

Mexico government has announced raising import tariffs on vehicles, two-wheelers, and auto parts

Published on 12-Dec-2025 09:00

Cipla launches Yurpeak (tirzepatide) therapy.

Cipla has announced the launch of Yurpeak (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes. 

Published on 11-Dec-2025 09:06

US Fed cuts interest rate range

US Federal Reserve cut interest rate to a range between 3.5% and 3.75%, the lowest level in almost 3-years at its 3rd consecutive meeting but signaled borrowing costs are unlikely to drop further in the near term. 

Published on 11-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status